Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,659Revenue (TTM) $M186Net Margin (%)-17.0Altman Z-Score1.6
Enterprise Value $M4,897EPS (TTM) $-0.2Operating Margin %-73.6Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.0Pre-tax Margin (%)-16.1Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.2Cash flow > EarningsN
Price/Sales24.85-y EBITDA Growth Rate %--Current Ratio3.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-5.4Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M194ROIC % (ttm)-99.8Gross Margin Increase y-yY

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ARIA is held by these investors:



ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2017-01-09Sell32,000$23.780.88view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-10-24Sell19,638$9.56150.94view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2016-10-03Sell47,384$13.4678.23view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-09-28Sell8,750$13.9871.6view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-09-22Sell20,000$13.4378.63view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-09-15Sell59,369$11.73104.52view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-08-22Sell19,436$10.47129.13view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-08-12Sell25,000$10.5128.48view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-07-22Sell18,286$8.11195.81view
Cole Hugh MSVP, Chief Business Officer 2016-06-28Sell6,012$7.05240.28view

Quarterly/Annual Reports about ARIA:

News about ARIA:

Articles On GuruFocus.com
GAMCO Analyst: Is VMware a Compelling Investment Idea in Data Infrastructure? Jun 26 2017 
Gabelli TV: 2017 American Water Works Annual Conference Recap Jun 26 2017 
Monthly Dividend Stocks to Pay Your Bills Jun 26 2017 
The Rubicon Project: Who Is Selling and Why It's Creating a Bargain Price Jun 26 2017 
Sports, Stocks and the Magic Quadrants Jun 26 2017 
GMO Global Equity Insights - Whiplash: On Value, Growth and Ignoring the Fundamentals Jun 26 2017 
Dan Loeb's Third Point Letter on $3.5 Billion Nestle Purchase, Plans to Sells L'Oreal Jun 26 2017 
Canaries in the Coal Mine – What to Watch as Stocks Continue to Make New Highs Jun 26 2017 
A Look at Darden Valuation Jun 26 2017 
Is Dollar Tree Oversold With Potential Cuts to SNAP? Jun 26 2017 

More From Other Websites
​SEC charges two former Ariad executives with insider trading Jun 27 2017
Analyzing Incyte’s Revenue Streams in 1Q17 Jun 15 2017
[$$] Big Sales by Biogen CFO Don't Deter Buying May 05 2017
Former Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale Apr 06 2017
Amgen's Blincyto sBLA Secures FDA Priority Review Mar 30 2017
Who Is Incyte Collaborating With? Mar 01 2017
Two Great Stock Ideas in the IBB Biotech ETF Feb 15 2017
ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib Feb 07 2017
Why Ariad Pharmaceuticals Stock Nearly Doubled in January Feb 06 2017
Ariad Submits Marketing Application to EU Agency Feb 06 2017
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European... Feb 06 2017
Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy... Feb 01 2017
Ariad mum on layoffs in letter to employees: ‘It’s business as usual’ Jan 25 2017
Ariad Put Off Potential Suitor Amid 'Aggressive' Takeda Bid: RBC Jan 20 2017
Ariad played hardball to boost Takeda buyout price, federal filings show Jan 20 2017
Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017 Jan 20 2017
Can The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)? Jan 20 2017
5 Expensive Drugs That Could End Up in Trump's Crosshairs Jan 18 2017
Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders Jan 18 2017
Jazz Begins Phase III Study for Label Expansion of Defitelio Jan 18 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}